Nexus Drugs Private Limited, a active private limited company, was established on 02 February 2001 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24243TG2001PTC036160. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹2.00 Cr and a paid-up capital of ₹2.00 Cr.
It upholds a compliant status. Its leadership includes Mallikarjun Koyilakonda (Director), Suresh Kilaru (Director). Past directors included Nannuri Lakshmi Prasanna, Pera Reddy Devarapally, Srinivasa Reddy Devireddy. It holds ₹1.11 Cr open charges and ₹1.00 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No 34, Flat No 201, Magistic Chambers East Srinivas Nagar, S R Nagar, Hyderabad, Telangana, 500038.
U24243TG2001PTC036160
036160
02 February 2001
₹2.00 Cr
₹2.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Nexus Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mallikarjun Koyilakonda | Director | 20 Oct 2023 | Current |
| Suresh Kilaru | Director | 13 Aug 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 15 Dec 2012 | Past |
| Pramod Abcsdd | Director | 02 Dec 2020 | Past |
| Pramod Abcsdd | Director | 02 Dec 2020 | Past |
| Pramod Abcsdd | Director | 20 Feb 2015 | Past |
| Pramod Abcsdd | Director | 06 Feb 2025 | Past |
| Pramod Abcsdd | Director | 30 May 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nexus Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.6% decrease. The company also saw a substantial improvement in profitability, with a 23.09% increase in profit. The company's net worth moved up by a moderate rise of 0.61%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Nexus Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹11,125,000.00
₹10,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Feb 2012 | Andhra Bank | ₹1.11 Cr | Open |
| 22 Dec 2009 | Andhra Bank | ₹1.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nexus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nexus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexus Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge registered on 22 Dec 2009 via Charge ID 10200926 with Andhra Bank was fully satisfied on 02 Dec 2024. was documented.
Progress on Nexus Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Nexus Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
Progress on Mallikarjun Koyilakonda was appointed as a Director was appointed as a Director on 20 Oct 2023 & has been associated with this company since 2 years 1 month . was documented.
Suresh Kilaru was appointed as a Director was appointed as a Director on 13 Aug 2020 & has been associated with this company since 5 years 3 months . was recorded as a recent event.
Progress on A charge with Andhra Bank of Rs. 1.11 Cr registered on 14 Feb 2012 with Charge ID 10341791 was modified on 13 Dec 2013. was documented.
The CIN of Nexus Drugs Private Limited is U24243TG2001PTC036160.
Nexus Drugs Private Limited is headquartered at Plot No 34, Flat No 201, Magistic Chambers East Srinivas Nagar, S R Nagar, Hyderabad, Telangana, 500038.
Nexus Drugs Private Limited was incorporated on 02 February 2001.
The current directors of Nexus Drugs Private Limited are
The primary industry of Nexus Drugs Private Limited is Manufacturing.
Nexus Drugs Private Limited is unlisted.
The authorized capital of Nexus Drugs Private Limited is ₹2.00 Cr, and the paid-up capital is ₹2.00 Cr.
The compliance status of Nexus Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX